The Boston Keratoprosthesis type II (BK2) device may be the only viable option to salvage vision in patients with severe cicatrizing ocular surface disease. The prior BK2 model was modified to the present day (click-on) model in 2009. The clinical outcomes of the current click-on BK2 model is discussed in this touchOPHTHALMOLOGY interview with Dr Chhavi Saini (Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA) as well as the clinical implications of these findings, and what further study is needed.
The presentation entitled ‘Clinical Outcomes of Boston Keratoprosthesis Type II – Results from the Current Click-on Model’ was presented at the American Society of Cataract and Refractive Surgery, April 22-26, 2022
Questions:
- Could you tell us a little about the Boston Keratoprosthesis type II (BK2) device and its advantages compared with the previous model?
- What were the aims and design of your study?
- What were the findings in terms of visual outcomes and complications?
- On the basis of these findings, what factors should be considered when assessing patient suitability for the current BK2 device?
- What questions remain unanswered and what further research is needed?
Disclosures: Chhavi Saini discloses grant/research support from Boston Keratoprosthesis Fund.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual ASCRS 2022.
